Palbociclib
- PDF / 169,351 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 158 Views
1
S
Febrile neutropenia: case report In a retrospective study involving 32 patients treated between December 2017 to August 2018, one patient [age and sex not stated] was described, who developed febrile neutropenia following treatment with palbociclib for breast cancer. The patient started receiving palbociclib [route not stated] 125 mg/day from day 1 to day 21, followed by a 7 day suspension period in a 28 day cycle. Additionally, the patient received unspecified endocrine therapy. Subsequently, the patient developed febrile neutropenia [duration of treatment to reaction onset and outcome not stated]. Author comment: [O]ne must handle administrations of Palbociclib carefully as it causes neutropenia frequently. There was only 1 case (3%) of febrile neutropenia observed among all cases. Iwamoto N, et al. Toxicity of Palbocidib in Patients Aged 70 Years and Older with Metastatic Breast Cancer. Gan to Kagaku Ryoho 46: 1137-1140, No. 7, Jul 2019. Available from: URL: https://www.ncbi.nlm.nih.gov/pubmed/31296819 [Japanese; 803437780 summarised from a translation] - Japan
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
